Literature DB >> 8927677

Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD).

C K Conners1, E D Levin, E Sparrow, S C Hinton, D Erhardt, W H Meck, J E Rose, J March.   

Abstract

Nicotine, like the psychostimulants methylphenidate and dextroamphetamine, acts as an indirect dopamine agonist and improves attention and arousal. Adults and adolescents with attention deficit hyperactivity disorder (ADHD) smoke much more frequently than normal individuals or those with other psychiatric conditions, perhaps as a form of self-medication for ADHD symptoms. Nicotine might therefore have some value as a treatment for ADHD. The present study is an acute double-blind crossover administration of nicotine and placebo with smokers (n = 6) and nonsmokers (n = 11) diagnosed with adult ADHD. The drug was delivered via a transdermal patch at a dosage of 7 mg/day for nonsmokers and 21 mg/day for smokers. Results indicate significant clinician-rated global improvement, self-rated vigor and concentration, and improved performance on chronometric measures of attention and timing accuracy. Side effects were minimal. These acute results indicate the need for a longer clinical trial and a comparison with other stimulants in adult ADHD treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8927677

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  62 in total

1.  Response requirement and increases in accuracy produced by stimulant drugs in a 5-choice serial reaction-time task in rats.

Authors:  Mikhail N Koffarnus; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2010-10-06       Impact factor: 4.530

2.  Manipulation of nicotinic acetylcholine receptors differentially affects behavioral inhibition in human subjects with and without disordered baseline impulsivity.

Authors:  Alexandra S Potter; David J Bucci; Paul A Newhouse
Journal:  Psychopharmacology (Berl)       Date:  2011-10-04       Impact factor: 4.530

3.  Anxiety and Depressed Mood Decline Following Smoking Abstinence in Adult Smokers with Attention Deficit Hyperactivity Disorder.

Authors:  Lirio S Covey; Mei-Chen Hu; Theresa Winhusen; Jennifer Lima; Ivan Berlin; Edward Nunes
Journal:  J Subst Abuse Treat       Date:  2015-07-17

4.  Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial.

Authors:  F Joseph McClernon; F Berry Hiott; Eric C Westman; Jed E Rose; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2006-09-15       Impact factor: 4.530

Review 5.  Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature.

Authors:  J Helen Yoo; Maria G Valdovinos; Dean C Williams
Journal:  J Autism Dev Disord       Date:  2007-01-13

6.  Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders.

Authors:  L Eugene Arnold; Michael G Aman; Jill Hollway; Elizabeth Hurt; Bethany Bates; Xiaobai Li; Cristan Farmer; Rene Anand; Susan Thompson; Yaser Ramadan; Craig Williams
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-04-26       Impact factor: 2.576

Review 7.  Constitutional mechanisms of vulnerability and resilience to nicotine dependence.

Authors:  N Hiroi; D Scott
Journal:  Mol Psychiatry       Date:  2009-02-24       Impact factor: 15.992

8.  Stimulant treatment of ADHD and cigarette smoking: a meta-analysis.

Authors:  Erin N Schoenfelder; Stephen V Faraone; Scott H Kollins
Journal:  Pediatrics       Date:  2014-05-12       Impact factor: 7.124

9.  Association of attention-deficit/hyperactivity disorder and conduct disorder with early tobacco and alcohol use.

Authors:  William B Brinkman; Jeffery N Epstein; Peggy Auinger; Leanne Tamm; Tanya E Froehlich
Journal:  Drug Alcohol Depend       Date:  2014-12-02       Impact factor: 4.492

10.  Methylphenidate does not influence smoking-reinforced responding or attentional performance in adult smokers with and without attention deficit hyperactivity disorder (ADHD).

Authors:  Scott H Kollins; Erin Schoenfelder; Joseph S English; F Joseph McClernon; Rachel E Dew; Scott D Lane
Journal:  Exp Clin Psychopharmacol       Date:  2013-10       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.